Combination of Statin plus Renin angiotensin system inhibition for the prevention or the treatment of atherosclerotic cardiovascular disease

Current Pharmaceutical Design

Volumn 20, Issue 40, 2014, Pages 6299-6305

  Athyros, Vasilios G ^a   Katsiki, Niki ^a   Karagiannis, Asterios ^a   Mikhailidis, Dimitri P ^b  

^a ARISTOTLE UNIVERSITY MEDICAL SCHOOL   (Greece)

^b ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

Cardiovascular disease; Combination; Endothelial function; Low grade inflammation; MicroRNA; Renin angiotensin system inhibitor; Statin

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MICRORNA; MICRORNA 146A; PHARMACOLOGY;

ARTICLE; ATHEROSCLEROSIS; ATHEROSCLEROTIC CARDIOVASCULAR DISEASE; ATHEROSCLEROTIC PLAQUE; CARDIOVASCULAR FUNCTION; CARDIOVASCULAR MORTALITY; CORONARY ARTERY ATHEROSCLEROSIS; DIABETES MELLITUS; DISEASE COURSE; DRUG EFFECTS; DRUG POTENTIATION; DRUG THERAPY; HIGH RISK PATIENT; HUMAN; HUMANS; HYPERTENSION; METABOLIC SYNDROME X; MORBIDITY; OBESITY; PHARMACEUTICAL CARE; PREVENTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RENIN-ANGIOTENSIN SYSTEM; VASCULITIS;

ATHEROSCLEROSIS; DRUG EFFECTS; DRUG THERAPY; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; PHARMACOLOGY; PREVENTION AND CONTROL; RENIN-ANGIOTENSIN SYSTEM;

EID: 84963938159     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/1381612820666140620115756     Document Type: Article

References (89)

1. [1] Global Health Observatory (GHO). Non communicable disease (NCD) mortality and morbidity. http://www.who.int/gho/ncd/mortality_morbidity/en/
2. [2] Deckers JW, Blumenthal RS. Statins for primary prevention of cardiovascular disease. BMJ 2011; 342: d1048.
3. [3] Cholesterol Treatment Trialists’ (CTT) Collaboration, Baigent C, Blackwell L, Emberson J, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 2010; 376: 1670-81.
4. [4] Fruchart JC, Sacks FM, Hermans MP, et al. Residual Risk Reduction Initiative (R3I): The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in dyslipidaemic patients. Diab Vasc Dis Res 2008; 5: 319-35.
5. [5] Chapman MJ, Ginsberg HN, Amarenco P, et al. European Atherosclerosis Society Consensus Panel: Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management. Eur Heart J 2011; 32: 1345-61.
6. [6] Reiner Z, Catapano AL, De Backer G, et al. ESC Committee for Practice Guidelines (CPG) 2008–2010 and 2010–2012 Committees: ESC/EAS guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J 2011; 32: 1769-818.
7. [7] Fruchart JC, Davignon J, Hermans MP, et al. Residual macrovascular risk in 2013: what have we learned? Cardiovasc Diabetol 2014; 13: 26.
8. [8] Rader DJ, Degoma EM. Future of cholesteryl ester transfer protein inhibitors. Annu Rev Med 2014; 65: 385-403.
9. [9] Athyros VG, Kakafika AI, Tziomalos K, Karagiannis A, Mikhailidis DP. Pleiotropic effects of statins--clinical evidence. Curr Pharm Des 2009; 15: 479-89.
10. [10] Koh KK, Han SH, Oh PC, Shin EK, Quon MJ. Combination therapy for treatment or prevention of atherosclerosis: focus on the lipid-RAAS interaction. Atherosclerosis 2010; 209: 307-13.
11. [11] Prabhakar SS. Inhibition of renin-angiotensin system: implications for diabetes control and prevention. J Investig Med 2013; 61: 551-7.
12. [12] Komers R. Renin inhibition in the treatment of diabetic kidney disease. Clin Sci (Lond) 2013; 124: 553-66.
13. [13] Leoncini G, Viazzi F, Pontremoli R. RAAS inhibition and renal protection. Curr Pharm Des 2012; 18: 971-80.
14. [14] Alfie J, Aparicio LS, Waisman GD. Current strategies to achieve further cardiac and renal protection through enhanced renin angiotensin-aldosterone system inhibition. Rev Recent Clin Trials 2011; 6: 134-46.
15. [15] Didangelos TP, Arsos GA, Karamitsos DT, Athyros VG, Georga SD, Karatzas ND. Effect of quinapril or losartan alone and in combination on left ventricular systolic and diastolic functions in asymptomatic patients with diabetic autonomic neuropathy. J Diabetes Complications 2006; 20: 1-7.
16. [16] Meune C, Wahbi K, Duboc D, Weber S. Meta-analysis of Renin-Angiotensin-aldosterone blockade for heart failure in presence of preserved left ventricular function. J Cardiovasc Pharmacol Ther 2011; 16: 368-75.
17. [17] Maejima Y, Nobori K, Ono Y, et al. Heart Failure by Coadministration of Statin and Angiotensin-II Receptor Blocker (HFCOSTAR) Trial Investigators. Synergistic effect of combined HMG-CoA reductase inhibitor and angiotensin-II receptor blocker therapy in patients with chronic heart failure: the HFCOSTAR trial. Circ J 2011; 75: 589-95.
18. [18] Koh KK, Ahn JY, Han SH, et al. Pleiotropic effects of angiotensin II receptor blocker in hypertensive patients. J Am Coll Cardiol 2003; 42: 905-10.
19. [19] Ismail H, Mitchell R, McFarlane SI, Makaryus AN. Pleiotropic effects of inhibitors of the RAAS in the diabetic population: above and beyond blood pressure lowering. Curr Diab Rep 2010; 10: 32-6.
20. [20] Jankowski P, Safar ME, Benetos A. Pleiotropic effects of drugs inhibiting the renin-angiotensin-aldosterone system. Curr Pharm Des 2009; 15: 571-84.
21. [21] Krysiak R, Okopie B. Pleiotropic effects of angiotensinconverting enzyme inhibitors in normotensive patients with coronary artery disease. Pharmacol Rep 2008; 60: 514-23.
22. [22] Athyros VG, Mikhailidis DP, Papageorgiou AA, et al. GREACE Study Collaborative Group. Effect of statins and ACE inhibitors alone and in combination on clinical outcome in patients with coronary heart disease. J Hum Hypertens 2004; 18: 781-8.
23. [23] Fujita M, Yamazaki T, Hayashi D, Kohro T, Okada Y, Nagai R; JCAD Study Investigators. Comparison of cardiovascular events in patients with angiographically documented coronary narrowing with combined renin-angiotensin system inhibitor plus statin versus renin-angiotensin system inhibitor alone versus statin alone (from the Japanese Coronary Artery Disease Study). Am J Cardiol 2007; 100: 1750-3.
24. [24] Japanese Coronary Artery Disease (JCAD) Study Investigators. Current status of the background of patients with coronary artery disease in Japan. Circ J 2006; 70: 1256-62.
25. [25] Sever PS, Poulter NR, Mastorantonakis S, Chang CL, Dahlof B, Wedel H; ASCOT Investigators. Coronary heart disease benefits from blood pressure and lipid-lowering. Int J Cardiol 2009; 135: 218-22.
26. [26] Dahlöf B, Sever PS, Poulter NR, et al. ASCOT Investigators. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOTBPLA): a multicentre randomised controlled trial. Lancet 2005; 366: 895-906.
27. [27] Mourad JJ. Which patients benefit the most from the perindopril/ amlodipine combination. J Hypertens 2011; 29 (1): S23-8.
28. [28] Spinar J, Vitovec J, Soucek M. Anti-hypertensive strategies in patients with MEtabolic parameters, DIabetes mellitus and/or NephropAthy (the MEDINA study). Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2013 Jul 29. [Epub ahead of print]
29. [29] Teo KK, Burton JR, Buller CE, et al. Long-term effects of cholesterol lowering and angiotensin-converting enzyme inhibition on coronary atherosclerosis: The Simvastatin/Enalapril Coronary Atherosclerosis Trial (SCAT). Circulation 2000; 102: 1748-54.
30. [30] Koh KK, Quon MJ, Han SH, et al. Additive beneficial effects of losartan combined with simvastatin in the treatment of hypercholesterolemic, hypertensive patients. Circulation 2004; 110: 3687-92.
31. [31] Liu Z, Zhao Y, Wei F, et al. Treatment with telmisartan/ rosuvastatin combination has a beneficial synergistic effect on ameliorating Th17/Treg functional imbalance in hypertensive patients with carotid atherosclerosis. Atherosclerosis 2014; 233: 291-9.
32. [32] Ceriello A, Assaloni R, Da Ros R, et al. Effect of atorvastatin and irbesartan, alone and in combination, on postprandial endothelial dysfunction, oxidative stress, and in inflammation in type 2 diabetic patients. Circulation 2005; 111: 2518-24.
33. [33] Ohshima K, Mogi M, Nakaoka H, et al. Inhibition of MCP-1/CCR2 signaling pathway is involved in synergistic inhibitory effects of irbesartan with rosuvastatin on vascular remodeling. J Am Soc Hypertens 2012; 6: 375-84.
34. [34] Tian XY, Wong WT, Xu A, et al. Rosuvastatin improves endothelial function in db/db mice: role of angiotensin II type 1 receptors and oxidative stress. Br J Pharmacol 2011; 164: 598-606.
35. [35] Grothusen C, Bley S, Selle T, et al. Combined effects of HMGCoA-reductase inhibition and renin-angiotensin system blockade on experimental atherosclerosis. Atherosclerosis 2005; 182: 57-69.
36. [36] Koh KK. Effects of statins on vascular wall: Vasomotor function, inflammation, and plaque stability. Cardiovasc Res 2000; 47: 648-57.
37. [37] Ruggenenti P, Perna A, Tonelli M, et al. ESPLANADE Study Group. Effects of add-on fluvastatin therapy in patients with chronic proteinuric nephropathy on dual reninangiotensin system blockade: the ESPLANADE trial. Clin J Am Soc Nephrol 2010; 5: 1928-38.
38. [38] Lee HY, Sakuma I, Ihm SH, Goh CW, Koh KK. Statins and Renin-Angiotensin system inhibitor combination treatment to prevent cardiovascular disease. Circ J 2014; 78: 281-7.
39. [39] Oubiña MP, de las Heras N, Cediel E, et al. Synergistic effect of angiotensin-converting enzyme (ACE) and 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA)reductase inhibition on inflammatory markers in atherosclerotic rabbits. Clin Sci (Lond) 2003; 105: 655-62.
40. [40] Athyros VG, Mikhailidis DP. Pharmacotherapy: statins and newonset diabetes mellitus--a matter for debate. Nat Rev Endocrinol 2012; 8: 133-4.
41. [41] Athyros VG, Elisaf MS, Alexandrides T, et al. Assessing the Treatment Effect in Metabolic Syndrome Without Perceptible Diabetes (ATTEMPT) Collaborative Group. Long-term impact of multifactorial treatment on new-onset diabetes and related cardiovascular events in metabolic syndrome: a post hoc ATTEMPT analysis. Angiology 2012; 63: 358-66.
42. [42] Wang KL, Liu CJ, Chao TF, et al. Risk of new-onset diabetes mellitus versus reduction in cardiovascular events with statin therapy. Am J Cardiol 2014; 113: 631-6.
43. [43] Athyros VG, Papageorgiou AA, Symeonidis AN, et al. GREACE Study Collaborative Group. Early benefit from structured care with atorvastatin in patients with coronary heart disease and diabetes mellitus. Angiology 2003; 54: 679-690.
44. [44] Athyros VG, Papageorgiou AA, Mercouris BR, et al. Treatment with atorvastatin to the National Cholesterol Educational Program goal versus 'usual' care in secondary coronary heart disease prevention. The GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) study. Curr Med Res Opin 2002; 18: 220-8.
45. [45] LaRosa JC, Grundy SM, Waters DD, et al. Treating to New Targets (TNT) Investigators. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 2005; 352(14): 1425-35.
46. [46] Waters DD, Ho JE, Boekholdt SM, et al. Cardiovascular event reduction versus new-onset diabetes during atorvastatin therapy: effect of baseline risk factors for diabetes. J Am Coll Cardiol 2013; 61: 148-52.
47. [47] Julius S, Kjeldsen SE, Weber M, et al. VALUE trial group. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004; 363: 2022-31.
48. [48] Julius S, Weber MA, Kjeldsen SE, et al. The Valsartan Antihypertensive Long-Term Use Evaluation (VALUE) trial: outcomes in patients receiving monotherapy. Hypertension 2006; 48: 385-91.
49. [49] Aksnes TA, Kjeldsen SE, Rostrup M, Omvik P, Hua TA, Julius S. Impact of new-onset diabetes mellitus on cardiac outcomes in the Valsartan Antihypertensive Long-term Use Evaluation (VALUE) trial population. Hypertension 2007; 50: 467-73.
50. [50] Verdecchia P, Reboldi G, Angeli F, et al. Adverse prognostic significance of new diabetes in treated hypertensive subjects. Hypertension 2004; 43: 963-9.
51. [51] Kostis JB, Wilson AC, Freudenberger RS, Cosgrove NM, Pressel SL, Davis BR; SHEP Collaborative Research Group. Long-term effect of diuretic-based therapy on fatal outcomes in subjects with isolated systolic hypertension with and without diabetes. Am J Cardiol 2005; 95: 29-35.
52. [52] Pan ZW, Lu YJ, Yang BF. MicroRNAs: a novel class of potential therapeutic targets for cardiovascular diseases. Acta Pharmacol Sin 2010; 31: 1-9.
53. [53] Wang Z, Luo X, Lu Y, Yang B. miRNAs at the heart of the matter. J Mol Med 2008; 86: 771-83.
54. [54] Latronico MV, Catalucci D, Condorelli G. Emerging role of microRNAs in cardiovascular biology. Circ Res 2007; 101: 1225-36.
55. [55] Latronico MV, Condorelli G. MicroRNAs and cardiac pathology. Nat Rev Cardiol 2009; 6: 419-29.
56. [56] Mishra PK, Tyagi N, Kumar M, Tyagi SC. MicroRNAs as a therapeutic target for cardiovascular diseases. J Cell Mol Med 2009; 13: 778-89.
57. [57] Lu X, Kakkar V. The Roles of MicroRNAs in Atherosclerosis. Curr Med Chem 2013 Dec 17. [Epub ahead of print]
58. [58] Zernecke A. MicroRNAs in the regulation of immune cell functions--implications for atherosclerotic vascular disease. Thromb Haemost 2012; 107: 626-33.
59. [59] Rayner KJ, Esau CC, Hussain FN, et al. Inhibition of miR-33a/b in non-human primates raises plasma HDL and lowers VLDL triglycerides. Nature 2011; 478: 404-7.
60. [60] Rayner KJ, Sheedy FJ, Esau CC, et al. Antagonism of miR-33 in mice promotes reverse cholesterol transport and regression of atherosclerosis. J Clin Invest 2011; 121: 2921-31.
61. [61] Rotllan N, Ramírez CM, Aryal B, Esau CC, Fernández-Hernando C. Therapeutic silencing of microRNA-33 inhibits the progression of atherosclerosis in Ldlr-/-mice--brief report. Arterioscler Thromb Vasc Biol 2013; 33: 1973-7.
62. [62] Mikhailidis DP, Athyros VG. Dyslipidaemia in 2013: New statin guidelines and promising novel therapeutics. Nat Rev Cardiol 2014; 11: 72-4.
63. [63] Bonauer A, Carmona G, Iwasaki M, et al. MicroRNAs-92a controls angiogenesis and functional recovery of ischemic tissues in mice. Science 2009; 324: 1710-3.
64. [64] Ho PC, Chang KC, Chuang YS, Wei LN. Cholesterol regulation of receptor-interacting protein 140 via microRNA-33 in inflammatory cytokine production. FASEB J 2011; 25: 1758-66.
65. [65] Minami Y, Satoh M, Maesawa C, et al. Effect of atorvastatin on microRNA 221/222 expression in endothelial progenitor cells obtained from patients with coronary artery disease. Eur J Clin Invest 2009; 39: 359-67.
66. [66] Tabuchi T, Satoh M, Itoh T, Nakamura M. MicroRNA-34a regulates the longevity-associated protein SIRT1 in coronary artery disease: effect of statins on SIRT1 and microRNA-34a expression. Clin Sci (Lond) 2012; 123: 161-71.
67. [67] Eskildsen TV, Jeppesen PL, Schneider M, et al. Angiotensin II Regulates microRNA-132/-212 in Hypertensive Rats and Humans. Int J Mol Sci 2013; 14: 11190-207.
68. [68] Nossent AY, Hansen JL, Doggen C, Quax PH, Sheikh SP, Rosendaal FR. SNPs in microRNA binding sites in 3-UTRs of RAAS genes influence arterial blood pressure and risk of myocardial infarction. Am J Hypertens 2011; 24: 999-1006
69. [69] Weber M, Baker MB, Patel RS, Quyyumi AA, Bao G, Searles CD. MicroRNA Expression Profile in CAD Patients and the Impact of ACEI/ARB. Cardiol Res Pract 2011; 2011: 532915.
70. [70] Takagi H, Mizuno Y, Yamamoto H, Goto SN, Umemoto T; All-Literature Investigation of Cardiovascular Evidence Group. Effects of telmisartan therapy on interleukin-6 and tumor necrosis factoralpha levels: a meta-analysis of randomized controlled trials. Hypertens Res 2013; 36: 368-73.
71. [71] Deiuliis J, Mihai G, Zhang J, et al. Renin-sensitive microRNAs correlate with atherosclerosis plaque progression. J Hum Hypertens 2013 Oct 24. [Epub ahead of print]
72. [72] Zhu N, Zhang D, Chen S, et al. Endothelial enriched microRNAs regulate angiotensin II-induced endothelial inflammation and migration. Atherosclerosis 2011; 215: 286-93.
73. [73] Sen A, Most P, Peppel K. Induction of microRNA-138 by proinflammatory cytokines causes endothelial cell dysfunction. FEBS Lett 2014 Jan 31. [Epub ahead of print]
74. [74] Methe H, Kim JO, Kofler S, Weis M, Nabauer M, Koglin J. Expansion of circulating Toll-like receptor 4-positive monocytes in patients with acute coronary syndrome. Circulation 2005; 111: 2654-61.
75. [75] Ishikawa Y, Satoh M, Itoh T, Minami Y, Takahashi Y, Akamura M. Local expression of Toll-like receptor 4 at the site of ruptured plaques in patients with acute myocardial infarction. Clin Sci 2008; 115: 133-40.
76. [76] Cai X, Lu S, Zhang Z, Gonzalez CM, Damania B, Cullen BR. Kaposi's sarcoma-associated herpesvirus expresses an array of viral microRNAs in latently infected cells. Proc. Natl. Acad. Sci. U.S.A. 2005; 102; 5570-5.
77. [77] Bentwich I, Avniel A, Karov Y, et al. Identification of hundreds of conserved and nonconserved human microRNAs. Nat Genet 2005; 37: 766-70.
78. [78] Taganov KD, Boldin MP, Chang KJ, Baltimore D. NF-Bdependent induction of microRNA miR-146, an inhibitor targeted to signaling proteins of innate immune responses. Proc Natl Acad Sci U.S.A. 2006; 103: 12481-6.
79. [79] Schmieder RE, Hilgers KF, Schlaich MP, Schmidt BM. Reninangiotensin system and cardiovascular risk. Lancet 2007; 369: 1208-19.
80. [80] Takahashi Y, Satoh M, Minami Y, Tabuchi T, Itoh T, Nakamura M. Expression of miR-146a/b is associated with the Toll-like receptor 4 signal in coronary artery disease: effect of reninangiotensin system blockade and statins on miRNA-146a/b and Toll-like receptor 4 levels. Clin Sci (Lond) 2010; 119: 395-405.
81. [81] Fujita M, Yamazaki T, Hayashi D, Kohro T, Okada Y, Nagai R; JCAD Study Investigators. Pleiotropic effects of statins on cardiovascular events in the Japanese Coronary Artery Disease study. Int J Cardiol 2008; 129: 294-6.
82. [82] Banach M, Nikfar S, Rahimi R, et al. Lipid and Blood Pressure Meta-Analysis Collaboration Group. The effects of statins on blood pressure in normotensive or hypertensive subjects-a meta-analysis of randomized controlled trials. Int J Cardiol 2013; 168: 2816-24.
83. [83] Hale LP, Craver KT, Berrier AM, Sheffield MV, Case LD, Owen J. Combination of fosinopril and pravastatin decreases platelet response to thrombin receptor agonist in monkeys. Arterioscler Thromb Vasc Biol 1998; 18: 1643-6.
84. [84] Siddiqui TI, Kumar KSA, Dikshit DK. Platelets and atherothrombosis: causes, targets and treatments for thrombosis. Curr Med Chem 2013; 20: 2779-97.
85. [85] Jagroop IA, Mikhailidis DP. Angiotensin II can induce and potentiate shape change in human platelets: effect of losartan. J Hum Hypertens 2000; 14: 581-5.
86. [86] Mitsios JV, Papathanasiou AI, Goudevenos JA, Tselepis AD. The antiplatelet and antithrombotic actions of statins. Curr Pharm Des 2010; 16: 3808-14.
87. [87] Tziomalos K, Karagiannis A, Athyros VG. Effects of lipidlowering agents on inflammation, hemostasis and blood pressure. Curr Pharm Des 2014 [in press].
88. [88] Koh KK, Lim S, Choi H, et al. Combination pravastatin and valsartan treatment has additive beneficial effects to simultaneously improve both metabolic and cardiovascular phenotypes beyond that of monotherapy with either drug in patients with primary hypercholesterolemia. Diabetes 2013; 62: 3547-52.
89. [89] Huang Z, Jansson L, Sjöholm A. Vasoactive drugs enhance pancreatic islet blood flow, augment insulin secretion and improve glucose tolerance in female rats. ClinSci (Lond) 2007; 112: 69-76.